Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VSTM Stock Forecast 2026-2027
$5.59
Current Price
$491.00M
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to VSTM Price Targets
+239.9%
To High Target of $19.00
+186.2%
To Median Target of $16.00
+150.4%
To Low Target of $14.00
VSTM Price Momentum
-0.7%
1 Week Change
-12.5%
1 Month Change
+23.7%
1 Year Change
-27.6%
Year-to-Date Change
-50.3%
From 52W High of $11.25
+39.4%
From 52W Low of $4.01
📊 TOP ANALYST CALLS
Did VSTM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Verastem is one of their latest high-conviction picks.
Latest VSTM Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, VSTM has a bullish consensus with a median price target of $16.00 (ranging from $14.00 to $19.00). The overall analyst rating is Strong Buy (9.8/10). Currently trading at $5.59, the median forecast implies a 186.2% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jeet Mukherjee at BTIG, projecting a 239.9% upside. Conversely, the most conservative target is provided by Sean Lee at HC Wainwright & Co., suggesting a 150.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VSTM Analyst Ratings
9
Buy
0
Hold
0
Sell
VSTM Price Target Range
Low
$14.00
Average
$16.00
High
$19.00
Current: $5.59
Latest VSTM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VSTM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 30, 2026 | Jefferies | Faisal Khurshid | Buy | Assumes | $15.00 |
| Mar 12, 2026 | BTIG | Jeet Mukherjee | Buy | Assumes | $19.00 |
| Feb 4, 2026 | HC Wainwright & Co. | Andres Y. Maldonado | Buy | Assumes | $18.00 |
| Oct 16, 2025 | Cantor Fitzgerald | Eric Schmidt | Overweight | Assumes | $N/A |
| Sep 9, 2025 | BTIG | Justin Zelin | Buy | Reiterates | $20.00 |
| Aug 8, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $13.00 |
| Jun 25, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $12.00 |
| May 9, 2025 | HC Wainwright & Co. | Sean Lee | Buy | Maintains | $14.00 |
| Apr 10, 2025 | Jefferies | Kelly Shi | Buy | Initiates | $15.00 |
| Apr 9, 2025 | Mizuho | Mara Goldstein | Outperform | Maintains | $8.00 |
| Mar 24, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $14.00 |
| Mar 24, 2025 | HC Wainwright & Co. | Sean Lee | Buy | Maintains | $10.00 |
| Mar 21, 2025 | RBC Capital | Gregory Renza | Outperform | Maintains | $14.00 |
| Jan 31, 2025 | B. Riley Securities | Kalpit Patel | Buy | Maintains | $9.00 |
| Jan 24, 2025 | Guggenheim | Michael Schmidt | Buy | Reiterates | $N/A |
| Jan 7, 2025 | RBC Capital | Gregory Renza | Outperform | Maintains | $16.00 |
| Dec 19, 2024 | Mizuho | Mara Goldstein | Outperform | Maintains | $9.00 |
| Dec 19, 2024 | HC Wainwright & Co. | Sean Lee | Buy | Reiterates | $7.00 |
| Oct 18, 2024 | Cantor Fitzgerald | Pete Stavropoulos | Overweight | Reiterates | $N/A |
| Oct 18, 2024 | HC Wainwright & Co. | Sean Lee | Buy | Reiterates | $7.00 |
Verastem Inc. (VSTM) Competitors
The following stocks are similar to Verastem based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Verastem Inc. (VSTM) Financial Data
Valuation Metrics
Market Cap
$491.00M
Enterprise Value
$363.52M
P/E Ratio
N/A
PEG Ratio
-4.6x
Price/Sales
15.3x
Growth & Margins
Revenue Growth (YoY)
+56.0%
Gross Margin
+83.5%
Operating Margin
-236.5%
Net Margin
+82.9%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+41.8%
Current Ratio
3.1x
Debt/Equity
152.4x
ROE
-1,480.2%
ROA
-61.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Verastem Inc. (VSTM) Business Model
About Verastem Inc.
What They Do
Develops innovative cancer therapies.
Business Model
Verastem Inc. operates as a biopharmaceutical company focusing on the development and commercialization of cancer therapies. The company generates revenue primarily through the sale of its targeted therapies, which are designed to disrupt cancer cell signaling and replication, addressing critical needs in oncology.
Additional Information
Headquartered in Needham, Massachusetts, Verastem is involved in advancing precision medicine through its research and development efforts aimed at hematologic malignancies and solid tumors. Its ongoing initiatives position it as a key player in the biopharmaceutical market, particularly in the quest for more effective cancer treatment options.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
102
CEO
Mr. Daniel W. Paterson
Country
United States
IPO Year
2012
Website
www.verastem.comVerastem Inc. (VSTM) Latest News & Analysis
Latest News
Quick Summary
Verastem Oncology (Nasdaq: VSTM) granted 141,000 restricted stock units to eleven new employees as an employment inducement, in compliance with Nasdaq Listing Rule 5635(c)(4).
Why It Matters
The grant of restricted stock units indicates Verastem's commitment to attracting talent, which can enhance innovation and drive future growth, impacting long-term stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The oncology sector is rapidly advancing with the integration of immunotherapy, AI, and targeted drugs, enhancing treatment options and driving long-term healthcare growth.
Why It Matters
Advancements in oncology, including immunotherapy and AI, indicate potential for increased market growth and investment opportunities in healthcare sectors focused on innovative treatments.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Verastem (VSTM) holds a "Buy" rating, with progress in KRAS G12D therapies and FDA approval for phase 2 trials of VS-7375. Key 2026 milestones include pivotal data from RAMP 205 and early VS-7375 results.
Why It Matters
Verastem's "Buy" rating reflects strong potential in targeted therapies, FDA backing for trials, and key 2026 milestones, signaling growth and investment opportunities in oncology.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Verastem Oncology (Nasdaq: VSTM) will present long-term data on its AVMAPKI™ FAKZYNJA™ combination therapy from the Phase 2 RAMP 201 trial at the SGO 2026 Annual Meeting.
Why It Matters
The presentation of new long-term data on AVMAPKI™ FAKZYNJA™ may boost Verastem's stock by highlighting potential efficacy in treating specific cancers, attracting investor interest and confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Verastem Oncology (Nasdaq: VSTM) has multiple abstracts accepted for the AACR Annual Meeting in April 2026, focusing on RAS/MAPK pathway-driven cancers.
Why It Matters
Verastem's accepted abstracts at a key cancer research conference highlight its ongoing RAS/MAPK drug development, potentially influencing stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?
29 days ago
Quick Summary
Analysts' price targets for Verastem (VSTM) suggest a potential 159.3% upside. Consensus on raised earnings estimates also signals positive outlook for the stock.
Why It Matters
Analysts' targets suggest significant upside for Verastem (VSTM), indicating potential growth. Consensus on earnings estimates further supports positive sentiment and possible stock appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About VSTM Stock
What is Verastem Inc.'s (VSTM) stock forecast for 2026?
Based on our analysis of 20 Wall Street analysts, Verastem Inc. (VSTM) has a median price target of $16.00. The highest price target is $19.00 and the lowest is $14.00.
Is VSTM stock a good investment in 2026?
According to current analyst ratings, VSTM has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.59. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VSTM stock?
Wall Street analysts predict VSTM stock could reach $16.00 in the next 12 months. This represents a 186.2% increase from the current price of $5.59. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Verastem Inc.'s business model?
Verastem Inc. operates as a biopharmaceutical company focusing on the development and commercialization of cancer therapies. The company generates revenue primarily through the sale of its targeted therapies, which are designed to disrupt cancer cell signaling and replication, addressing critical needs in oncology.
What is the highest forecasted price for VSTM Verastem Inc.?
The highest price target for VSTM is $19.00 from Jeet Mukherjee at BTIG, which represents a 239.9% increase from the current price of $5.59.
What is the lowest forecasted price for VSTM Verastem Inc.?
The lowest price target for VSTM is $14.00 from Sean Lee at HC Wainwright & Co., which represents a 150.4% increase from the current price of $5.59.
What is the overall VSTM consensus from analysts for Verastem Inc.?
The overall analyst consensus for VSTM is bullish. Out of 20 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are VSTM stock price projections?
Stock price projections, including those for Verastem Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 4:20 AM UTC